Fulcrum Equity Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $639K | Buy |
3,443
+44
| +1% | +$8.17K | 0.66% | 42 |
|
|
2025
Q1 | $712K | Sell |
3,399
-272
| -7% | -$57K | 0.78% | 39 |
|
|
2024
Q4 | $652K | Sell |
3,671
-3,534
| -49% | -$628K | 0.65% | 52 |
|
|
2024
Q3 | $1.42M | Sell |
7,205
-862
| -11% | -$170K | 1.2% | 14 |
|
|
2024
Q2 | $1.38M | Buy |
8,067
+1,295
| +19% | +$222K | 1.24% | 13 |
|
|
2024
Q1 | $1.23M | Buy |
6,772
+1,860
| +38% | +$339K | 1.45% | 21 |
|
|
2023
Q4 | $761K | Buy |
4,912
+124
| +3% | +$19.2K | 0.94% | 23 |
|
|
2023
Q3 | $714K | Buy |
4,788
+1,620
| +51% | +$241K | 0.84% | 34 |
|
|
2023
Q2 | $427K | Buy |
3,168
+45
| +1% | +$6.06K | 0.5% | 51 |
|
|
2023
Q1 | $498K | Buy |
3,123
+1,547
| +98% | +$247K | 0.47% | 56 |
|
|
2022
Q4 | $255K | Buy |
+1,576
| New | +$255K | 0.21% | 61 |
|
|
2022
Q1 | – | Sell |
-2,352
| Closed | -$318K | – | 106 |
|
|
2021
Q4 | $318K | Sell |
2,352
-53
| -2% | -$7.17K | 0.12% | 123 |
|
|
2021
Q3 | $259K | Buy |
2,405
+20
| +0.8% | +$2.15K | 0.1% | 147 |
|
|
2021
Q2 | $269K | Buy |
2,385
+191
| +9% | +$21.5K | 0.1% | 157 |
|
|
2021
Q1 | $237K | Buy |
2,194
+163
| +8% | +$17.6K | 0.09% | 158 |
|
|
2020
Q4 | $218K | Buy |
+2,031
| New | +$218K | 0.09% | 149 |
|
|
2020
Q3 | – | Sell |
-3,991
| Closed | -$392K | – | 145 |
|
|
2020
Q2 | $392K | Buy |
3,991
+731
| +22% | +$71.8K | 0.19% | 101 |
|
|
2020
Q1 | $248K | Sell |
3,260
-1,623
| -33% | -$123K | 0.18% | 40 |
|
|
2019
Q4 | $432K | Sell |
4,883
-236
| -5% | -$20.9K | 0.23% | 68 |
|
|
2019
Q3 | $388K | Buy |
5,119
+192
| +4% | +$14.6K | 0.2% | 66 |
|
|
2019
Q2 | $323K | Buy |
4,927
+1,354
| +38% | +$88.8K | 0.15% | 70 |
|
|
2019
Q1 | $288K | Buy |
3,573
+32
| +0.9% | +$2.58K | 0.1% | 79 |
|
|
2018
Q4 | $326K | Buy |
+3,541
| New | +$326K | 0.12% | 42 |
|